A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Aimin Tang, Zhifeng Chen, Kara S. Cox, Hua-Poo Su, Cheryl Callahan, Arthur Fridman, Lan Zhang, Sangita B. Patel, Pedro J. Cejas, Ryan Swoyer, Sinoeun Touch, Michael P. Citron, Dhanasekaran Govindarajan, Bin Luo, Michael Eddins, John C. Reid, Stephen M. Soisson, Jennifer Galli, Dai Wang, Zhiyun Wen, Gwendolyn J. Heidecker, Danilo R. Casimiro, Daniel J. DiStefano and Kalpit A. Vora ()
Additional contact information
Aimin Tang: Merck & Co., Inc
Zhifeng Chen: Merck & Co., Inc
Kara S. Cox: Merck & Co., Inc
Hua-Poo Su: Merck & Co., Inc
Cheryl Callahan: Merck & Co., Inc
Arthur Fridman: Merck & Co., Inc.
Lan Zhang: Merck & Co., Inc
Sangita B. Patel: Merck & Co., Inc
Pedro J. Cejas: Merck & Co., Inc
Ryan Swoyer: Merck & Co., Inc
Sinoeun Touch: Merck & Co., Inc
Michael P. Citron: Merck & Co., Inc
Dhanasekaran Govindarajan: Merck & Co., Inc
Bin Luo: Merck & Co., Inc.
Michael Eddins: Merck & Co., Inc
John C. Reid: Merck & Co., Inc
Stephen M. Soisson: Merck & Co., Inc
Jennifer Galli: Merck & Co., Inc
Dai Wang: Merck & Co., Inc
Zhiyun Wen: Merck & Co., Inc
Gwendolyn J. Heidecker: Merck & Co., Inc
Danilo R. Casimiro: Merck & Co., Inc
Daniel J. DiStefano: Merck & Co., Inc
Kalpit A. Vora: Merck & Co., Inc

Nature Communications, 2019, vol. 10, issue 1, 1-13

Abstract: Abstract Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-019-12137-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12137-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-12137-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().